Evidence map›Paper›PMID 30855276›Full record

ArticleThe Journal of clinical investigation2019

A maresin 1/RORα/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis.

Yong-Hyun Han, Kyong-Oh Shin, Ju-Yeon Kim, Daulat B Khadka, Hyeon-Ji Kim, Yong-Moon Lee, Won-Jea Cho, Ji-Young Cha, Bong-Jin Lee, Mi-Ock Lee

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. A New Synthetic Analogue of Protectin DX With Enhanced Therapeutic Potential Against Metabolic-Associated Steatotic Liver Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yong-Hyun HanCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Kyong-Oh ShinCollege of Pharmacy, Chungbuk National University, Cheongju, South Korea.
Ju-Yeon KimCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Daulat B KhadkaCollege of Pharmacy, Chonnam National University, Gwangju, South Korea.
Hyeon-Ji KimCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Yong-Moon LeeCollege of Pharmacy, Chungbuk National University, Cheongju, South Korea.
Won-Jea ChoCollege of Pharmacy, Chonnam National University, Gwangju, South Korea.
Ji-Young ChaLaboratory of Cell Metabolism and Gene Regulation, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, South Korea.
Bong-Jin LeeCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Mi-Ock LeeCollege of Pharmacy, Seoul National University, Seoul, South Korea.
Seoul National University · KRChonnam National University · KRChungbuk National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoic acid-related orphan receptor α (RORα) is considered a key regulator of polarization in liver macrophages that is closely related to nonalcoholic steatohepatitis (NASH) pathogenesis. However, hepatic microenvironments that support the function of RORα as a polarity regulator were largely unknown. Here, we identified maresin 1 (MaR1), a docosahexaenoic acid (DHA) metabolite with a function of specialized proresolving mediator, as an endogenous ligand of RORα. MaR1 enhanced the expression and transcriptional activity of RORα and thereby increased the M2 polarity of liver macrophages. Administration of MaR1 protected mice from high-fat diet-induced NASH in a RORα-dependent manner. Surprisingly, RORα increased the level of MaR1 through transcriptional induction of 12-lipoxygenase (12-LOX), a key enzyme in MaR1 biosynthesis. Furthermore, we demonstrated that modulation of 12-LOX activity enhanced the protective function of DHA against NASH. Together, these results suggest that the MaR1/RORα/12-LOX autoregulatory circuit could offer potential therapeutic strategies for curing NASH.

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsArachidonate 12-LipoxygenaseDietary FatsDocosahexaenoic AcidsHumansInflammationMacrophagesMaleMiceMice, KnockoutNuclear Receptor Subfamily 1, Group F, Member 17,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acidArachidonate 12-LipoxygenaseDietary FatsDocosahexaenoic AcidsNuclear Receptor Subfamily 1, Group F, Member 1RORA protein, humanRora protein, mouseHepatitisHepatologyInflammationMacrophagesMolecular pathology

Identifiers

PMID30855276
PMCPMC6436872
OpenAlexW2921132259

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.